Ion Beam Applications (IBA) is the market leader in advanced cancer radiation therapy technologies. The company’s expertise lies in the development of innovative proton therapy technologies for cancer patients and suppling the oncological world with world class equipment. IBA’s therapy leads to a 50% to 80% lower risk of causing secondary cancer compared to traditional x-rays therapy. Cancer is among the leading causes of mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. The number of new cases is expected to rise by about 70% over the next 2 decades. The company is listed on the NYSE Euronext Brussels.